Deep learning and single-cell phenotyping for rapid antimicrobial susceptibility detection in Escherichia coli.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
14 11 2023
Historique:
received: 02 02 2023
accepted: 30 10 2023
medline: 16 11 2023
pubmed: 15 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

The rise of antimicrobial resistance (AMR) is one of the greatest public health challenges, already causing up to 1.2 million deaths annually and rising. Current culture-based turnaround times for bacterial identification in clinical samples and antimicrobial susceptibility testing (AST) are typically 18-24 h. We present a novel proof-of-concept methodological advance in susceptibility testing based on the deep-learning of single-cell specific morphological phenotypes directly associated with antimicrobial susceptibility in Escherichia coli. Our models can reliably (80% single-cell accuracy) classify untreated and treated susceptible cells for a lab-reference fully susceptible E. coli strain, across four antibiotics (ciprofloxacin, gentamicin, rifampicin and co-amoxiclav). For ciprofloxacin, we demonstrate our models reveal significant (p < 0.001) differences between bacterial cell populations affected and unaffected by antibiotic treatment, and show that given treatment with a fixed concentration of 10 mg/L over 30 min these phenotypic effects correlate with clinical susceptibility defined by established clinical breakpoints. Deploying our approach on cell populations from six E. coli strains obtained from human bloodstream infections with varying degrees of ciprofloxacin resistance and treated with a range of ciprofloxacin concentrations, we show single-cell phenotyping has the potential to provide equivalent information to growth-based AST assays, but in as little as 30 min.

Identifiants

pubmed: 37964031
doi: 10.1038/s42003-023-05524-4
pii: 10.1038/s42003-023-05524-4
pmc: PMC10645916
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ciprofloxacin 5E8K9I0O4U

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1164

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S008896/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N018656/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 110164/Z/15/Z
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR200915
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Cell. 2018 Feb 8;172(4):771-783.e18
pubmed: 29358050
Anal Chem. 2018 May 15;90(10):6314-6322
pubmed: 29677440
J Clin Microbiol. 2017 Dec 26;56(1):
pubmed: 29118168
J Antimicrob Chemother. 2018 Jun 1;73(6):1452-1459
pubmed: 29438542
Clin Microbiol Rev. 2015 Jan;28(1):191-207
pubmed: 25567227
Clin Microbiol Infect. 2020 Oct;26(10):1310-1317
pubmed: 32217160
Acc Chem Res. 2022 Jan 18;55(2):123-133
pubmed: 34898173
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):9170-9175
pubmed: 28790187
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16169-74
pubmed: 24046367
Appl Environ Microbiol. 2014 Aug;80(16):4977-86
pubmed: 24907320
Clin Chem. 2022 Jul 27;68(8):1064-1074
pubmed: 35714147
Front Microbiol. 2016 Oct 03;7:1558
pubmed: 27752253
EBioMedicine. 2022 Aug;82:104145
pubmed: 35864063
Genome Med. 2021 Sep 3;13(1):144
pubmed: 34479643
Clin Microbiol Infect. 2015 Apr;21(4):313-22
pubmed: 25753137
Sci Rep. 2021 Sep 16;11(1):18444
pubmed: 34531449
JAMA. 2020 Mar 03;323(9):844-853
pubmed: 32125404
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
ACS Nano. 2020 Nov 24;14(11):15336-15348
pubmed: 33095005
Appl Environ Microbiol. 1997 Jun;63(6):2421-31
pubmed: 9172364
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10270-10279
pubmed: 31068473
Commun Biol. 2022 Jul 9;5(1):688
pubmed: 35810255
Nat Commun. 2020 Oct 21;11(1):5328
pubmed: 33087704
Front Cell Infect Microbiol. 2020 Jul 15;10:308
pubmed: 32760676
J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500
pubmed: 32780112
Clin Microbiol Infect. 2019 May;25(5):555-561
pubmed: 30472426
Sci Transl Med. 2014 Dec 17;6(267):267ra174
pubmed: 25520395
Nat Methods. 2021 Jan;18(1):100-106
pubmed: 33318659
EBioMedicine. 2016 Jan 18;4:95-103
pubmed: 26981574
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30745382
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227291
Nat Commun. 2022 Oct 20;13(1):6215
pubmed: 36266330
Microbiome. 2022 Aug 24;10(1):134
pubmed: 35999570
mSystems. 2021 May 18;6(3):
pubmed: 34006623
J Antimicrob Chemother. 2022 Aug 25;77(9):2536-2545
pubmed: 35723965
IEEE Sens J. 2020 May 1;20(9):4940-4950
pubmed: 32440258
ACS Omega. 2021 Jun 15;6(25):16273-16279
pubmed: 34235297
Nat Commun. 2017 Mar 06;8:14618
pubmed: 28262707
Clin Infect Dis. 2009 Dec 1;49(11):1749-55
pubmed: 19857164
Diagnostics (Basel). 2019 May 03;9(2):
pubmed: 31058811
ACS Omega. 2022 Aug 12;7(33):29443-29451
pubmed: 36033656
Bioinformatics. 2022 Jan 3;38(2):325-334
pubmed: 34613360
Pathology. 2021 Dec;53(7):902-911
pubmed: 34274166

Auteurs

Alexander Zagajewski (A)

Department of Physics, University of Oxford, Parks Road, Oxford, OX1 3PJ, UK.
Kavli Institute for Nanoscience Discovery, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.

Piers Turner (P)

Department of Physics, University of Oxford, Parks Road, Oxford, OX1 3PJ, UK.
Kavli Institute for Nanoscience Discovery, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.

Conor Feehily (C)

Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.

Hafez El Sayyed (H)

Department of Physics, University of Oxford, Parks Road, Oxford, OX1 3PJ, UK.
Kavli Institute for Nanoscience Discovery, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.

Monique Andersson (M)

Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.

Lucinda Barrett (L)

Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.

Sarah Oakley (S)

Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.

Mathew Stracy (M)

Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.

Derrick Crook (D)

Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.

Christoffer Nellåker (C)

Nuffield Department of Women's & Reproductive Health, University of Oxford, Big Data Institute, Oxford, OX3 7LF, UK. christoffer.nellaker@wrh.ox.ac.uk.

Nicole Stoesser (N)

Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK. nicole.stoesser@ndm.ox.ac.uk.
Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. nicole.stoesser@ndm.ox.ac.uk.

Achillefs N Kapanidis (AN)

Department of Physics, University of Oxford, Parks Road, Oxford, OX1 3PJ, UK. achillefs.kapanidis@physics.ox.ac.uk.
Kavli Institute for Nanoscience Discovery, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK. achillefs.kapanidis@physics.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH